CLYM NASDAQ Week ended 24 Jul 2026

Weekly Investor Report

Climb Bio Inc · Healthcare · Biotechnology

Open interactive chart View report data Download investor PDF
Latest close 12.84 USD
1.1% latest week
Weekly setup

Mixed setup

The weekly trend is active. Price is 48.7% above the Trend Line and sits at 87.9% of its 52-week range. The latest completed week returned 1.1%, after a -1.8% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive. Options positioning is volatility with 69/100 conviction, while the latest news-sentiment score is 53/100. Near-term considerations: volume confirmation is below normal; earnings are due in 13d.

Setup score 67 out of 100
Latest Close 12.84 USD 24 Jul 2026
1W Return 1.1% latest completed week
4W Return -1.8% short-term follow-through
12W Return 44.1% quarterly tape
Trend Breadth 94.2% 49 of 52 weeks active
Volume Ratio 0.7x vs 13-week average
What is working
  • The trend backdrop is active with a 49-week active streak.
  • Price is above the Trend Line, keeping the weekly tape constructive.
  • Price is above Fair Value, showing premium demand versus the model.
  • Activity pressure is positive on the latest completed week.
What could go wrong
  • 9 reversal markers appear in the recent smart-money tape.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through 1.1% Latest completed week; four-week move -1.8%. Indicator stack 97/76 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. Options pressure Volatility 69/100 conviction; expected move 23.0%. News sentiment 53/100 50 relevant articles in the latest sentiment read. Event risk 13d Next report is scheduled for 11 Aug 2026; event risk rises as the date approaches.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is active. Price is 48.7% above the Trend Line and sits at 87.9% of its 52-week range. The latest completed week returned 1.1%, after a -1.8% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 0.7x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
30 Jan 6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.9212-week average 0.94

12-week confirmation

Trend active12/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure12/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership12/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.92Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers99 reversal markers

No recent accumulation markers. 9 reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is -1.8% over four weeks, 44.1% over 12 weeks, and 785.5% over one year. The current trend has remained active for 49 consecutive weeks.

Performance by holding period

1W1.1%
4W-1.8%
12W44.1%
26W155.8%
52W785.5%
Active trend streak49 weeks
Active weeks in one year49
Trend breadth94.2%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure1.53Latest activity-pressure read.
Pressure change-18.7%Four-week change in activity pressure.
Leadership106.54Latest relative-leadership reading.
RS change-21.6%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.

Open full factor analysis
Factor week 26 Jul 2026 Financial statements through 31 Dec 2025 Field coverage 67% Model confidence 64%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength67/100Blend of value, momentum, and quality. Underlying universe rank 34; rank 1 is best.
Value58/100Relative valuation strength. Underlying universe rank 43; rank 1 is best.
Quality56/100Profitability and accounting quality. Underlying universe rank 45; rank 1 is best.
Momentum58/100Medium-term price momentum. Underlying universe rank 43; rank 1 is best.
Growth58/100Revenue and earnings growth. Underlying universe rank 43; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
-
Price divided by trailing earnings.
Price / sales
-
Market value relative to trailing revenue.
EV / EBITDA
-
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
-7.3%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
-
Gross profit retained from each unit of revenue.
Operating margin
-
Operating profit retained from revenue.
Free-cash-flow margin
-
Free cash flow generated from revenue.
Return on invested capital
-28.2%
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
-
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-
Latest one-year free-cash-flow growth.
Piotroski F-score
2/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
0.0%
Net share repurchases relative to market value.
Shareholder yield
0.0%
Dividend yield plus net buyback yield.
Net debt / EBITDA
0.1x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Options positioningVolatility

CLYM shows volatility options pressure with a 69/100 conviction score, put-call volume ratio of 0.00, expected move of 23.0%, and Sharemaestro trend signal active.

Conviction69/100
Expected move23.0%
Put/call volume0.00
Pressure100
Speculation32
Volatility96
Trend agreement38
Open options detail
Insider activity-

No recent insider transactions are stored for this company.

News sentiment53/100

Weighted news tone is neutral across 50 relevant articles.

12 positive · 36 neutral · 2 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings13dNext report is scheduled for 11 Aug 2026; event risk rises as the date approaches.
Options expected move23.0%Nearest-chain priced movement where available.
52-week drawdown-10.9%Distance below the 52-week high.
13-week volatility9.3%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher14 of 2612 weeks finished lower.
Best week+28.2%Week of 10 Apr.
Worst week-13.1%Week of 20 Mar.
Latest week+1.1%Week of 24 Jul.

Shape of recent returns

Strong gains10
Modest gains4
Flat weeks0
Modest losses7
Sharp losses5
Recent vol9.3%13-week weekly-return volatility.
Base vol16.5%52-week weekly-return volatility.
Up/down split29/22Count of positive and negative weeks in the 52-week window.
Average skew15.3% / -7.4%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape68/100

Trend, activity pressure, participation, and risk combine to a 68/100 tape read.

 Indicator analysis82/100

Latest 12-week confirmation: trend 12/12, activity pressure 12/12, relative leadership 12/12.

Activity pressure 0.92; 9 reversal markers Factors59/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 47; Small Cap Core rank 49 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Options51/100

CLYM shows volatility options pressure with a 69/100 conviction score, put-call volume ratio of 0.00, expected move of 23.0%, and Sharemaestro trend signal active.

Volatility · Volatility expansion watch · Expected move 23.0% Sentiment53/100

Weighted news tone is neutral across 50 relevant articles.

Climb Bio Inc (CLYM) Technical Analysis: Support, Resistance, Indicators & Moving Averages Insiders50/100

No recent insider transaction evidence is stored.

 Earnings13d

Next report is scheduled for 11 Aug 2026; event risk rises as the date approaches.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
24 Jul 202612.84 USD1.1%8.63 USD4.32 USD1.53106.544.3MOn
17 Jul 202612.70 USD-9.3%8.37 USD4.26 USD2.00108.165.9MOn
10 Jul 202614.00 USD8.5%8.09 USD4.19 USD2.10127.697.7MOn
3 Jul 202612.90 USD-1.4%7.72 USD4.12 USD1.96122.085.8MOn
26 Jun 202613.08 USD14.2%7.35 USD4.06 USD1.89135.9111.7MOn
19 Jun 202611.45 USD0.1%6.98 USD3.99 USD1.81105.454.2MOn
12 Jun 202611.44 USD8.4%6.65 USD3.93 USD1.97118.098.5MOn
5 Jun 202610.55 USD-3.7%6.33 USD3.88 USD2.03113.367.4MOn
29 May 202610.96 USD-0.4%6.04 USD3.83 USD2.25119.083.2MOn
22 May 202611.00 USD1.9%5.75 USD3.78 USD2.27134.602.9MOn
15 May 202610.80 USD-5.0%5.45 USD3.73 USD2.30142.413.0MOn
8 May 202611.37 USD27.6%5.15 USD3.68 USD2.22164.716.0MOn
1 May 20268.91 USD-2.5%4.83 USD3.62 USD1.97128.717.2MOn
24 Apr 20269.14 USD-0.2%4.60 USD3.59 USD1.58146.963.7MOn
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.